trending Market Intelligence /marketintelligence/en/news-insights/trending/l8ahvx8dWVGmj1MDtjCBog2 content esgSubNav
In This List

CRISPR, Intellia, Caribou, ERS Genomics sign agreement for gene editing tech IP

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


CRISPR, Intellia, Caribou, ERS Genomics sign agreement for gene editing tech IP

CRISPR Therapeutics signed a global cross-consent and invention management agreement with Intellia Therapeutics Inc., Caribou Biosciences and ERS Genomics for the foundational intellectual property covering CRISPR/Cas9 gene editing technology.

Under the agreement, the parties will maintain and coordinate the prosecution, defense and enforcement of the shared CRISPR/Cas9 foundational patent portfolio worldwide. Additionally, co-owners of the intellectual property will allow cross-consents to all existing and future licenses and sublicenses based on the rights of another co-owner.

Other parties to the agreement include intellectual property co-owners Regents of the University of California, Emmanuelle Charpentier and the University of Vienna.